
nkarta

ENGINEERING Natural Killer Cells

for next generation treatment of cancer and autoimmune diseases

ON DEMAND



Forward-looking statements

This presentation contains forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, regarding future events and the future results of the company that are based on current expectations, estimates, forecasts, and projections about the industry in which the company operates and the future of our business, future plans and strategies, projections, anticipated trends and events, the economy, and other future conditions, and the beliefs and assumptions of the management of the company. Words such as "address," "anticipate," "believe," "consider," "continue," "develop," "estimate," "expect," "further," "goal," "intend," "may," "plan," "potential," "project," "seek," "should," "target," "will," variations of such words, and similar expressions are intended to identify such forward-looking statements. Such statements reflect the current views of the company and its management with respect to future events and are subject to inherent risks, uncertainties, and changes in circumstances that are difficult to predict and may be outside our control. Therefore, you should not rely on any of these forward-looking statements. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, the company's actual results, performance, or achievements could differ materially from the results expressed in, or implied by, these forward-looking statements. Please see section entitled "Risk Factors" in our annual, quarterly and other filings with the Securities and Exchange Commission for a description of these risks and uncertainties.

This presentation has been prepared by the company based on information it has obtained from sources it believes to be reliable. Summaries of documents contained in this presentation may not be complete. The company does not represent that the information herein is complete. The information in this presentation is current only as of the date on the cover, and the company's business or financial condition and other information in this presentation may change after that date. The company undertakes no obligation to update any forward-looking statements in order to reflect any event or circumstance occurring after the date of this presentation or currently unknown facts or conditions.

Interim data from clinical trials are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more data on existing patients become available. The clinical trial programs are ongoing, and the final results may be materially different from those reflected in any interim data the company reports. Further, others, including regulatory agencies, may not accept or agree with the company's assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product and the value of the company in general. In addition, the information the company chooses to publicly disclose regarding a particular study or clinical trial is typically a summary of extensive information, and you or others may not agree with what the company determines is the material or otherwise appropriate information to include in its disclosure, and any information the company determines not to disclose may ultimately be deemed significant with respect to future decisions, conclusions, views, activities or otherwise regarding a particular product, product candidate or business.

Delivering the future of cell therapy by harnessing the killing ability of natural killer (NK) cells


Fully allogeneic from healthy, pre-screened donors

On-demand, off-the-shelf availability for outpatient administration

Programs in autoimmune disease and oncology

Multiple clinical updates expected in 2024

Cash runway into 2026



CAR NK Cell

CARs engineered for optimal target cell killing

Candidates engineered with a targeting CAR and membrane bound IL-15

Pipeline with transformational potential


Program (Target)	Indication	Research	IND-Enabling	Clinical	Status
NKX019 (CD19)	Lupus Nephritis (SLE)	0	0		IND cleared 4Q 2023 First patient enrollment expected 1H 2024
NKX019 (CD19)	r/r NHL	0	0	—0	Phase 1 dose-compression cohort ongoing Update planned mid 2024
NKX101 (NKG2D)	r/r AML	0	0	—-O	Phase 1 ongoing Update planned 1H 2024
NKX101 (NKG2D)	Solid Tumors	0	O		Gated on proof of concept in r/r AML
NKX070 (CD70)	Heme & Solid Tumors	0			Collaboration CRISPR
NK + T (Undisclosed)	Undisclosed	$\bigcirc \longrightarrow$			Collaboration CRISPR
Autoimmune	Oncology				

nkarta

AML, acute myeloid leukemia; NHL, non-Hodgkin lymphoma; r/r: relapsed or refractory; SLE, systemic lupus erythematosus

NKX019 in Autoimmune Disease





Cell therapy offers a promise of a disease-modifying option for patients with refractory autoimmune disease


Autoimmune disease is a major unmet need

- Estimated 7 million patients in U.S. with a form of B-cell mediated autoimmune disease¹
- Pathogenic B cells can drive systemic diseases via combination of intrinsic and extrinsic factors

Effectiveness of current therapies is inadequate and often consists of lifelong immune suppression

CD19-directed cell therapy has challenged the treatment paradigm for autoimmune diseases

 Drug-free remissions after a single treatment in academic trials²



Tsokos, *N Engl J Med* 2011; 365:2110-2121.


Target, not only modality, may explain benefits of CD19 cell therapy compared to historical responses to B cell-targeting

Benefit of CD19-directed CAR T in SLE may be via elimination of autoantibody-producing cells

- CD19^{high} CD20^{neg/dim} plasmablasts
- CD19^{neg/dim} CD20^{neg} long-lived plasma cells

Current agents that target B cells have inconsistent benefit in SLE

- Rituximab (CD20 antibody)
- Belimumab (BAFF-R antibody)




von Büdingen, et al. Eur Neurol 2015;73:238-246.


CAR T cell kinetics in autoimmune disease differ greatly from oncology

Transient persistence is followed by rapid elimination in autoimmune disease

- Expansion peaks at ~10 days
- Less antigen burden may explain differences in persistence and exposure

In B cell malignancies, CAR T cells persist long after antigen-dependent expansion





B cell malignancy

Mackensen et al. Nature Med. 28 Oct 22. 2124–2132.


Transient B-cell suppression can provide treatment-free responses in autoimmune disease

Immune "reset" occurs after B cell suppression as short as 50 days in autoimmune disease

- Persistent B cell aplasia is <u>NOT required</u> for long-term responses
- Autoantibodies remain negative in most patients and drug-free remissions persist


Prolonged B cell aplasia is common in oncology (median ~18 mo¹), especially in responders

- Absence of B cells is used as clinical proxy for detection and activity of CAR T cells
- B cell recovery within 3 months of infusion is associated with disease progression



Autoimmune

B cell malignancy



Baird, et al. 2021. Blood Advances 5(1):143-155.

nkarta


Muller et al. Abstract 220, ASH 2023. 1: Bhoj, et al. *Blood. 2016 Jul 21; 128(3): 360–370*.


NKX019 targets and kills cells from patients across indications

Patient samples from ongoing NHL trial show effective elimination of CD19+ cells from circulation by NKX019


- Normal and malignant cells cleared with a single cycle
- One cycle includes lymphodepletion and 3 doses of NKX019
- Deep suppression achieved by day 30

In vitro studies using blood from patients with various autoimmune diseases show consistent B cell killing





Disease-tailored lymphodepletion with cyclophosphamide alone could provide a critical advantage for patients with autoimmune disease



Early C_{max} of NK cells may lessen need for prolonged suppression provided by fludarabine

- LD is tailored to limit chemotherapy exposure as delayed peak effect offers less benefit for NK cells
- Elimination of fludarabine also lessens risks of cytopenias, infection, and secondary MDS¹

Historical use of single agent Cy at same dosage offers additional benefits


- Rheumatology providers and patients more familiar with Cy
- Possible regulatory advantage leveraging prior studies and real-world evidence

Autologous CD19 CAR T cells require fludarabine-containing LD for maximal exposure due to induction of endogenous cytokines, especially IL-15


Despite no immune barrier, autologous CAR T cells depend on multi-agent LD for elimination of "cytokine sink" to facilitate expansion

- Fludarabine-sparing LD results in limited CAR T expansion and benefit
- IL-15 levels peak shortly after infusion and correlate with expansion

Lower peak IL-15 levels associated with decreased responses in CAR T¹



NKX019 engineering allows cytokine independence, further enabling disease-tailored LD



Autocrine stimulation by membrane-bound IL-15 (mb-IL15) provides pro-survival signal


- mb-IL15 allows NKX019 to survive several weeks without supplemental cytokines like IL-15 or IL-2
- Construct causes no secreted IL-15 and has limited cross-cell stimulation

Autoimmune B cells may be more accessible than malignant B cells

While CD19 allows effective targeting of normal and abnormal cells of B cell lineage, multiple factors may make B cells in autoimmune disease more accessible to killing

Autoimmune Disease

- S Widespread antigen escape via downregulation or loss of CD19 by malignant B cells
- **N** Tumor microenvironment preventing trafficking and infiltration
- S Large cell burden and tumor infrastructure



B-cell malignancies

Adapted from: Baker, et al. Nature 2023 Jul;619(7971):707-715.

CD19 CAR NK cells may be ideally suited for autoimmune disease

NK cells reach peak activity at infusion for rapid target activity

- Maximal immediate effect without *in vivo* expansion
- T cells require expansion and necessitate a different LD approach


Allogeneic NK cells are cleared by host immunity

- Low risk of prolonged B-cell aplasia which is <u>not required for response</u>
- Long-lived CAR T cells have FDA-issued risk of T-cell malignancy¹

Superior safety and accessibility in non-malignant setting

- On-demand availability without need for cumbersome infrastructure at treatment centers
- Low risk of expansion-related toxicities including CRS and ICANS

NKX019 CAR NK for autoimmune diseases: A multicenter, open-label, phase 1 study



Endpoints:

- Safety and tolerability
- Pharmacokinetics
- Renal function
- Autoantibody serology

Off the shelf administration reduces burden to patients and providers


First patient dosing expected 1H 2024

Opportunity to investigate broader applicability of NKX019 in multiple autoimmune diseases

nkarta CAR: chimeric antigen receptor

NKX019 and NKX101 in oncology





NKX019

CD19 CAR NK in r/r non-Hodgkin lymphoma



Autologous CAR T-cell therapy has set the bar for cellular therapies in r/r NHL but has limitations

CAR T-cell therapy is not broadly accessible

- Only 20-30% of patients with LBCL who could benefit from CAR T receive it
- Patients often need to change providers and receive bridging chemotherapy

Potential toxicity requires proximity to a specialized inpatient treatment center

- Over 25% of patients require ICU care
- Grade 3+ CRS: 13 to 49%, Grade 3+ ICANS / neurotoxicity: 18 to 31%

Only 30-40% of patients with LBCL treated with CAR T-cell therapy have 6-month CR


- No ability to re-dose for incomplete response
- Outcomes among those that relapse are poor

YESCARTA USPI; KYMRIAH USPI; BREYANZI USPI; Azoulay et al, 2020; Tomas, et al. 2022.



NKX019 for B-cell malignancies: A multicenter, open-label, phase 1 study in r/r NHL

CRS, cytokine release syndrome; ICANS, immune effector cell-associated neurotoxicity syndrome



NKX019 Amendment: Compressed Dosing

Dose compression cohort enrolling patients with large B-cell lymphoma (LBCL), targeting patients who have received *prior CD19 CAR-T cell therapy*

New compressed dosing schedule to intensify exposure to NKX019 in the first week after LD

NKX019 on Days 0, 3, and 7 following standard LD with Flu/Cy

Previous cohorts received NKX019 on Days 0, 7 and 14

Study amendment also includes

- Potential higher doses of CAR NK cells
- Tailored LD with Cy monotherapy for patients with prolonged cytopenias
- Elimination of inpatient requirement
- Streamlined protocol assessments to reduce burden on sites and patients


Next clinical update planned for mid-2024



NKX019 has superior target cell killing compared to CD19 CAR T cells, even with low levels of CD19 expression

High CD19 Expressing Cells

Low CD19 Expressing Cells



CD19 downregulation allows normal and malignant B cells to escape CAR T cells¹ NKX019 maintains superior killing in B cell tumor cells expressing low CD19 levels² Potentially allows a deeper B cell immune reset in autoimmune disease



Nalm6 cells engineered to express varying levels of CD19 were obtained from R. Majzner, Stanford; Effector : Target is the ratio of NK or T cells to tumor cells.

NKX101

NKG2D CAR NK in r/r acute myeloid leukemia





AML is a rapidly progressing leukemia with a poor prognosis

Heterogenous group of blood cancers treated with risk-adapted chemotherapy


• Most patients will ultimately die from relapse or complications from therapy

Allogeneic HCT is best chance of long-term cure

- Limited to patients who are fit
- **Pre-HCT CR** improves outcomes

Outcomes for patients who relapse or have refractory disease are especially poor

- Low response rates with standard chemotherapy
- 12-18% CR rate, including venetoclax-based regimens



Survival of relapsed AML

Years


NKX101 for relapsed/refractory AML following disease-tailored LD

Fludarabine/Ara-C with anthracycline (e.g. FLAG-Ida) is a frequent salvage regimen for r/r AML with true CR rate of ~10% and cCR rate of ~20% as a comparator arm

• Anthracyclines (idarubicin, mitoxantrone, etc.) add toxicity and limit addressable population

Ara-C (cytarabine) is a DNA damaging agent with potent immunosuppressive effects

• Incorporated across AML treatment landscape, including upfront therapy



Roboz, et al *J Clin Oncol.* 2014 Jun 20;32(18):1919-26. Perl, et al *N Engl J Med.* 2019 Oct 31;381(18):1728-1740. Holubova, et al. *Int J Mol Sci.* 2019 Jul 15;20(14):3472. Ogbomo, et al. *Neoplasia.* 2008 Dec; 10(12): 1402–1410.

ASH 2023: Updated follow-up of patients with r/r AML

4 of 6 patients achieved CR/CRi


- High-risk features such as prior HCT, TP53 mutation and high blast burden
- 3 of 4 remained in CR/CRi at 4 months

Safety profile consistent with available therapies

- No CRS, ICANS or GvHD of any grade
- Myelosuppression and infection were the most common ≥Grade 3 toxicities

Next clinical update planned for 1H 2024

- 12-20 additional patients
- Additional follow-up for initial patients




Deep disease control with NKX101 with Flu/Ara-C lymphodepletion

Figure 1. Four of six patients had CR/CRi (67%), with three achieving CR. Patients 1 and 6 had no detectable minimum residual disease (MRD) by flow cytometry after one treatment cycle. Patient 3 had MRD of 0.18% after one cycle and was immediately taken to consolidative hematopoietic cell transplant. Patient 2 had three cycles of treatment with successive decrease in disease burden, resulting in CRi. Data as of October 31, 2023.

Of those who achieved CR/CRi, three out of four remained in CR/CRi at 4 months.

Sauter, et al. ASH 2023

Disease-tailored lymphodepletion does not compromise PK




- NKX101 dosed on days 0, 7, and 14
- Exposure consistent with previously published data using haploidentical NK cells¹
- No need for exogenous IL-2 or other cytokine support

Ara-C upregulates NKG2D ligands and increases sensitivity to NK cell killing


Ligands are upregulated with stress, including chemotherapy

- NKG2D CAR binds to 8 known ligands
- Mediates natural target cell elimination




Pre-treatment of AML cells increases sensitivity to NK killing in vitro

- Dose dependent effect
- May increase opportunity for CARmediated killing



Summary





Autoimmune expansion | 2024 updates | Cash runway

- Pipeline expanded into autoimmune disease
- Further investment in oncology gated by clinical signals from next data updates
- \$278.4 M in cash and cash equivalents as of 30 Sept 2023
- Projected cash runway into 2026

• Multiple clinical updates expected in 2024

Anticipated 2024 clinical milestones

1H 2024	<i>NKX019 in lupus nephritis -</i> Dose first patient and program update
1H 2024	<i>NKX101 in AML</i> - Clinical data from 12 to 20 new patients in flu/Ara-C cohort
Mid 2024	<i>NKX019 in NHL</i> - Clinical data from dose compression cohort in patients with LBCL after prior CAR-T